The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRAL | +203.33% | N/A | N/A | +633% |
| S&P | +13.95% | +78.35% | +12.25% | +28% |
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Learn about some of the leading cancer stocks in the U.S. stock market this year.
Investors are getting excited by the prospects for Grail's Galleri test in 2026.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $36.19M | 26.3% |
| Gross Profit | -$17,341.00K | 22.0% |
| Gross Margin | -47.91% | 29.7% |
| Market Cap | $2.13B | 398.9% |
| Market Cap / Employee | $2.13M | 0.0% |
| Employees | 1K | 0.0% |
| Net Income | -$88,977.00K | 29.2% |
| EBITDA | -$86,309.00K | 31.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $126.89M | -85.1% |
| Accounts Receivable | $16.28M | 7.0% |
| Inventory | 18.4 | -13.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.57M | -24.0% |
| Short Term Debt | $14.02M | 3.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.21% | 0.0% |
| Return On Invested Capital | -77.62% | -0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$63,629.00K | 39.7% |
| Operating Free Cash Flow | -$63,245.00K | 39.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.23 | 0.35 | 0.75 | 0.92 | 481.01% |
| Price to Sales | 4.82 | 6.70 | 13.71 | 15.06 | 287.89% |
| Price to Tangible Book Value | 1.11 | 1.78 | 4.21 | 5.40 | 669.39% |
| Enterprise Value to EBITDA | 0.92 | -2.33 | -14.01 | -19.17 | -840.07% |
| Return on Equity | -65.9% | -62.2% | -17.7% | -16.8% | - |
| Total Debt | $68.14M | $64.32M | $62.16M | $58.59M | -18.84% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
